<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>animascover.txt
<TEXT>


               SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C. 20549


                            FORM 8K

                        Current Report
               Pursuant to Section 13 or 15(d) of
              The Securities Exchange Act of 1934



  Date of Report (Date of earliest event reported):
                     December 16, 2005


                        JOHNSON & JOHNSON

     (Exact name of registrant as specified in its charter)


    New Jersey          1-3215             22-1024240

(State or other       Commission        (I.R.S. Employer
jurisdiction          File Number)      Identification No.)
of incorporation)



 One Johnson & Johnson Plaza, New Brunswick, New Jersey
08933

     (Address of principal executive offices)    (zip code)


Registrant's telephone number including area code:
                    (732) 524-0400

Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-
2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-
4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Item 8.01 Other Events

NEW   BRUNSWICK,  N.J.  and  WEST  CHESTER,  Pa.,  Dec.   16
/PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ)  and
Animas  Corporation  (Nasdaq:  PUMP),  an  insulin  delivery
company,  today  announced  a definitive  agreement  whereby
Animas   will   be  acquired  in  a  cash-for-stock   merger
transaction. Animas is expected to operate as a  stand-alone
entity reporting through LifeScan, Inc., a Johnson & Johnson
company  offering  blood  glucose  monitoring  systems.  The
acquisition affords LifeScan immediate entry into the  fast-
growing insulin delivery pump market.

Under  the terms of the agreement, Animas stockholders  will
receive  $24.50 for each outstanding Animas share.  The  net
value of the transaction as of the anticipated closing  date
is  estimated  to be approximately $518 million  based  upon
Animas' 22 million fully diluted shares outstanding, net  of
estimated cash on hand at time of closing.

The boards of directors of Johnson & Johnson and Animas have
approved  the  transaction, which is  subject  to  clearance
under  the  Hart-Scott-Rodino  Antitrust  Improvements  Act,
certain  foreign  regulatory approvals,  Animas  stockholder
approval   and  other  customary  closing  conditions.   The
transaction  is  expected to close in the first  quarter  of
2006.


Exhibit No.       Description of Exhibit

99.15     Press Release dated December 16, 2005





                       SIGNATURE



Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto
duly authorized.



                    JOHNSON & JOHNSON




Date: December 16, 2005    By: /s/ Stephen J. Cosgrove
                               Stephen J. Cosgrove
                               Chief Accounting Officer




</TEXT>
</DOCUMENT>